Stock Analiz

Abvc Biopharma, Inc. ABVC

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.91Market cap $25M
Open the interactive analysis →

Abvc Biopharma, Inc. (ABVC) is a healthcare company listed in the US with a market value of about $25M. In fiscal year 2025 it had revenue of $296000 and net income of -$8M, a net margin of -2671.8%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -9% a year, a 5-year average ROIC of -138%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Abvc Biopharma

Abvc Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $50M in 2015 to $296000 in 2025, a decline of about 40.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 535% over three years (dilution for shareholders). It spends 41% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S82.9
P/B1.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)-41.9%
Revenue growth (5 yrs, per year)-9.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2809.0%
ROIC (5-yr avg.)-138.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$296000$509589$152430$969783$355797$483045$701719$6956——
Net income-$8M-$5M-$8M-$16M-$13M-$11M-$4M-$6M-$4M-$11M
Free cash flow——-$4M-$8M-$8M—————
EPS (diluted)$-0.39$-0.42$-1.80$-5.19$-5.10$-5.00$-2.10$-0.20$-0.20$-0.60
Net margin-2671.8%-962.1%-5109.3%-1693.5%-3608.5%-2193.1%-560.5%-87184.2%——
ROIC-41.0%-170.2%-163.8%-229.4%-85.4%-154.8%-147.0%———

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Abvc Biopharma stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Abvc Biopharma pay a dividend?

Not currently.

Is Abvc Biopharma a good stock to buy?

We do not give buy or sell advice. Abvc Biopharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.